Tag: anti-obesity drugs

Altcoins

Novo Nordisk Downgrade: Semaglutide Patent Risks in 2026

TD Cowen just downgraded Novo Nordisk to Hold, slashing the price target as semaglutide patent losses loom in key markets....

10/03/2026

7 views

Read More

Global Companies

Eli Lilly Boosts Employer Coverage for Obesity Drugs

Eli Lilly just rolled out a program that could finally make powerful obesity medications affordable through your job's benefits. What...

05/03/2026

4 views

Read More

Altcoins

Novo Nordisk Ireland Expansion Challenges Eli Lilly

Novo Nordisk just poured over $500 million into an Irish facility to ramp up production of their game-changing Wegovy pill....

02/03/2026

4 views

Read More

Market News

Novo Nordisk CagriSema: Next Steps After Trial Setback

Novo Nordisk's CagriSema showed 23% weight loss but fell short of Zepbound's results in a head-to-head trial, sending shares tumbling....

26/02/2026

3 views

Read More

Market News

Novo Nordisk Stock Tumbles After CagriSema Trial Setback

Novo Nordisk's next big obesity hope, CagriSema, just fell short in a crucial head-to-head trial against a rival powerhouse—triggering a...

26/02/2026

3 views

Read More

Altcoins

Novo Nordisk Plunges: CagriSema Trial Falls Short

When Novo Nordisk's next-generation obesity shot CagriSema posted weaker weight loss numbers than expected against a key rival, shares cratered...

26/02/2026

4 views

Read More

Market News

Eli Lilly Widens Lead in Obesity Drug Race Over Novo Nordisk

Eli Lilly just landed another major blow to Novo Nordisk in the high-stakes obesity drug battle. With Zepbound showing superior...

24/02/2026

3 views

Read More

Altcoins

Jim Cramer’s Top 10 Stock Market Insights February 23 2026

Wall Street braces for a down open as Trump ups tariffs to 15% after Supreme Court ruling. Eli Lilly surges...

23/02/2026

4 views

Read More

Market News

Pharma’s Big Reset: Patent Cliffs and Pipelines in 2026

As pharma giants stare down a multi-billion patent cliff in 2026, pipelines and M&A become survival tools. But with China...

13/02/2026

13 views

Read More

Market News

Novo Nordisk’s Tough 2026: Obesity Drug Battles Ahead

Novo Nordisk kicked off 2026 with a blockbuster oral obesity pill launch, but lawsuits, disappointing guidance, and fierce competition have...

11/02/2026

4 views

Read More